1 - 10 out of 213Page size: 10
  1. 2023

  2. Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019

    van der Straten, L., Levin, M-D., Dinnessen, M. A. W., Visser, O., Posthuma, E. F. M., Doorduijn, J. K., Langerak, A. W., Kater, A. P. & Dinmohamed, A. G., Dec 2023, In: Blood cancer journal. 13, 1, p. 15 1 p., 15.

    Research output: Contribution to journal › Article › Academic › peer-review

  3. A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies

    Lameris, R., Ruben, J. M., Iglesias-Guimarais, V., de Jong, M., Veth, M., van de Bovenkamp, F. S., de Weerdt, I., Kater, A. P., Zweegman, S., Horbach, S., Riedl, T., Winograd, B., Roovers, R. C., Adang, A. E. P., de Gruijl, T. D., Parren, P. W. H. I. & van der Vliet, H. J., 21 Mar 2023, In: Cell Reports Medicine. 4, 3, p. 100961 100961.

    Research output: Contribution to journal › Article › Academic › peer-review

  4. Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation

    Thus, Y. J., de Rooij, M. F. M., Swier, N., Beijersbergen, R. L., Guikema, J. E. J., Kersten, M-J., Eldering, E., Pals, S. T., Kater, A. P. & Spaargaren, M., 1 Mar 2023, In: Haematologica. 108, 3, p. 797-810 14 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  5. Chronic lymphocytic leukemia presence impairs antigen-specific CD8+ T-cell responses through epigenetic reprogramming towards short-lived effectors

    Martens, A. W. J., Kavazovi?, I., Krapi?, M., Pack, S. M., Arens, R., Jongejan, A., Moerland, P. D., Eldering, E., van der Windt, G. J. W., Wensveen, F. M., Peters, F. S. & Kater, A. P., Mar 2023, In: Leukemia. 37, 3, p. 606-616 11 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  6. Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: a randomized, controlled trial

    Huygens, S., Hofsink, Q., Nijhof, I. S., Goorhuis, A., Kater, A. P., Te Boekhorst, P. A., Swaneveld, F., Novotný, V. M., Bogers, S., Welkers, M. R., Papageorgiou, G., Rijnders, B. J. & Heijmans, J., 11 Jan 2023, In: The Journal of infectious diseases. 227, 2, p. 206-210 5 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  7. Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

    Kielbassa, K., Haselager, M. V., Bax, D. J. C., van Driel, B. F., Dubois, J., Levin, M-D., Kersting, S., Svanberg, R., Niemann, C. U., Kater, A. P. & Eldering, E., 2023, (E-pub ahead of print) In: Leukemia.

    Research output: Contribution to journal › Article › Academic › peer-review

  8. 2022

  9. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

    Antic, D., Milic, N., Chatzikonstantinou, T., Scarfò, L., Otasevic, V., Rajovic, N., Allsup, D., Alonso Cabrero, A., Andres, M., Baile Gonzales, M., Capasso, A., Collado, R., Cordoba, R., Cuéllar-García, C., Correa, J. G., De Paoli, L., De Paolis, M. R., Del Poeta, G., Dimou, M., Doubek, M., & 81 othersEfstathopoulou, M., El-Ashwah, S., Enrico, A., Espinet, B., Farina, L., Ferrari, A., Foglietta, M., Lopez-Garcia, A., García-Marco, J. A., García-Serra, R., Gentile, M., Gimeno, E., da Silva, M. G., Gutwein, O., Hakobyan, Y. K., Herishanu, Y., Hernández-Rivas, J. Á., Herold, T., Itchaki, G., Jaksic, O., Janssens, A., Kalashnikova, O. B., Kalicińska, E., Kater, A. P., Kersting, S., Koren-Michowitz, M., Labrador, J., Lad, D., Laurenti, L., Fresa, A., Levin, M-D., Mayor Bastida, C., Malerba, L., Marasca, R., Marchetti, M., Marquet, J., Mihaljevic, B., Milosevic, I., Mirás, F., Morawska, M., Motta, M., Munir, T., Murru, R., Nunes, R., Olivieri, J., Pavlovsky, M. A., Piskunova, I., Popov, V. M., Quaglia, F. M., Quaresmini, G., Reda, G., Rigolin, G. M., Shrestha, A., Šimkovič, M., Smirnova, S., Špaček, M., Sportoletti, P., Stanca, O., Stavroyianni, N., Te Raa, D., Tomic, K., Tonino, S., Trentin, L., Van Der Spek, E., van Gelder, M., Varettoni, M., Visentin, A., Vitale, C., Vukovic, V., Wasik-Szczepanek, E., Wróbel, T., Segundo, L. Y. S., Yassin, M., Coscia, M., Rambaldi, A., Montserrat, E., Foà, R., Cuneo, A., Carrier, M., Ghia, P. & Stamatopoulos, K., Dec 2022, In: JOURNAL OF HEMATOLOGY & ONCOLOGY. 15, 1, p. 116 116.

    Research output: Contribution to journal › Article › Academic › peer-review

  10. SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma

    Leeksma, A. C., Derks, I. A. M., Garrick, B., Jongejan, A., Colombo, M., Bloedjes, T., Trowe, T., Leisten, J. C., Howarth, M., Malek, M., Mortensen, D. S., Blease, K., Groza, M. C., Narla, R. K., Loos, R., Kersten, M-J., Moerland, P. D., Guikema, J. E. J., Kater, A. P., Eldering, E., & 1 othersFilvaroff, E. H., 18 Nov 2022, (E-pub ahead of print) In: Molecular oncology.

    Research output: Contribution to journal › Article › Academic › peer-review

  11. Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19

    COBRA KAI Study Team, Haggenburg, S., Hofsink, Q., Lissenberg-Witte, B. I., Broers, A. E. C., van Doesum, J. A., van Binnendijk, R. S., den Hartog, G., Bhoekhan, M. S., Haverkate, N. J. E., Burger, J. A., Bouhuijs, J. H., Smits, G. P., Wouters, D., van Leeuwen, E. M. M., Bontkes, H. J., Kootstra, N. A., Zweegman, S., Kater, A. P., Heemskerk, M. H. M., & 9 othersGroen, K., van Meerten, T., Mutsaers, P. G. N. J., Beaumont, T., van Gils, M. J., Goorhuis, A., Rutten, C. E., Hazenberg, M. D. & Nijhof, I. S., 1 Oct 2022, In: JAMA oncology. 8, 10, p. 1477-1483 7 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  12. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study

    Munir, T., Moreno, C., Owen, C., Follows, G., Benjamini, O., Janssens, A., Levin, M-D., Osterborg, A., Robak, T., Simkovic, M., Stevens, D., Voloshin, S., Vorobyev, V., Yagci, M., Ysebaert, L., Qi, Q., Steele, A., Schuier, N., Baeten, K., Caces, D. B., & 2 othersNiemann, C. & Kater, A., 1 Oct 2022, In: Clinical lymphoma, myeloma & leukemia. 22, p. S264-S265

    Research output: Contribution to journal › Article › Academic › peer-review

Previous 1 2 3 4 5 6 7 8 ...22 Next

ID: 64520